0001193125-23-274071.txt : 20231109 0001193125-23-274071.hdr.sgml : 20231109 20231109074359 ACCESSION NUMBER: 0001193125-23-274071 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 231390105 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d263099d8k.htm FORM 8-K Form 8-K
false 0000860730 0000860730 2023-11-09 2023-11-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 9, 2023

 

 

HCA Healthcare, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-11239   27-3865930

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

One Park Plaza, Nashville,

Tennessee

  37203
(Address of Principal Executive Offices)   (Zip Code)

(615) 344-9551

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $.01 par value per share   HCA   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 7.01.

Regulation FD Disclosure.

On November 9, 2023, HCA Healthcare, Inc. (the “Company”) issued a press release providing an early perspective on 2024 and long-term financial targets ahead of its Investor Day. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The Company will stream the presentations and the management question and answer portion of its Investor Day and will make conference materials available on its Investor Relations page (https://investor.hcahealthcare.com/events-and-presentations/default.aspx). A replay will be available on the Company website beginning Friday, November 10, 2023 at 4:00 p.m. CT.

The information in this Item 7.01, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits:

 

Exhibit

No.

   Description
99.1    Press Release, dated November 9, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HCA HEALTHCARE, INC. (Registrant)
By:  

/s/ William B. Rutherford

  William B. Rutherford
  Executive Vice President and Chief Financial Officer

Date: November 9, 2023

EX-99.1 2 d263099dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

     

FOR IMMEDIATE RELEASE

 

 

INVESTOR CONTACT:

         MEDIA CONTACT:
Frank Morgan          Harlow Sumerford
615-344-2688          615-344-1851

HCA HEALTHCARE PROVIDES BUSINESS OUTLOOK

AHEAD OF INVESTOR DAY

Nashville, Tenn., November 9, 2023 – HCA Healthcare, Inc. (NYSE:HCA) will host its Investor Day today beginning at 8:00 a.m. CT. A team of HCA Healthcare leaders will offer perspectives on the Company’s financial performance, operations, and strategy to drive growth and create value.

Long-term Targets and Early Perspective on 2024

As part of Investor Day, the Company will discuss its strategic assessment of market opportunities and capital capacity. Based on this assessment, and subject to certain underlying assumptions, it is currently targeting over the next five years:

 

   

Adjusted EBITDA growth between 4% and 6%; and

   

Diluted earnings per share growth between 8% and 12%.

The Company’s targeted annual growth ranges are a composite of anticipated results over time. Actual performance in any given year may vary from these ranges for a variety of reasons.

“While our planning process for 2024 is not complete, we currently believe that our 2024 expectations will fall within the targeted ranges above, after considering the resolution of disputed claims with a commercial payer recorded in the first quarter of 2023,” said Sam Hazen, Chief Executive Officer of HCA Healthcare. “As usual we will give more detailed guidance during our year-end call in January.”

The long-term targets and early perspective on 2024 are based on current plans and expectations and are subject to a number of known and unknown uncertainties and risks, including those set forth below in “Forward-Looking Statements.”

2023 Investor Day

The Company will stream the presentations and the management question and answer portion of Investor Day and will make conference materials available on its Investor Relations page (https://investor.hcahealthcare.com/events-and-presentations/default.aspx). Investor Day is expected to conclude at approximately 3:45 p.m. CT. A replay will be available on the Company website beginning Friday, November 10, 2023 at 4:00 p.m. CT.

 

1


About the Company

As of September 30, 2023, HCA operated 183 hospitals and approximately 2,300 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include early perspectives on the outlook for 2024 and longer-term financial targets, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative,” “continue” or “target.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) changes in or related to general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions (and the impact thereof on the economy, financial markets and banking industry); changes in revenues due to declining patient volumes; changes in payer mix (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; supply shortages and disruptions; and the impact of potential federal government shutdowns, (2) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, (3) the impact of current and future federal and state health reform initiatives and possible changes to other federal, state or local laws and regulations affecting the health care industry, including, but not limited to, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), additional changes to the Affordable Care Act, its implementation, or interpretation (including through executive orders and court challenges), and proposals to expand coverage of federally-funded insurance programs as an alternative to private insurance or establish a single-payer system (such reforms often referred to as “Medicare for All”), (4) the effects related to the implementation of sequestration spending reductions required under the Budget Control Act of 2011, related legislation extending these reductions and those required under the Pay-As-You-Go Act of 2010 as a result of the federal budget deficit impact of the American Rescue Plan Act of 2021, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, attain expected levels of patient volumes and revenues, and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to health care providers and insurers and the size of the uninsured or underinsured population, (8) personnel-related capacity constraints, increases in wages and the ability to attract, utilize and retain qualified management and other personnel, including affiliated physicians, nurses and medical and technical support personnel, (9) the highly competitive nature of the health care business, (10) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (11) the efforts of health insurers, health care providers, large employer

 

2


groups and others to contain health care costs, (12) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) developments related to COVID-19, including, without limitation, the length and severity of COVID-19-related impacts and the spread of virus strains with new epidemiological characteristics; the volume of canceled or rescheduled procedures and the volume and acuity of COVID-19 patients cared for across our health systems; and measures we are taking to respond to COVID-19, (16) the emergence of and effects related to pandemics, epidemics and infectious diseases, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (21) the impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of actual and potential cybersecurity incidents or security breaches, including the data security incident disclosed in July 2023, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, physical risks from climate change or similar events beyond our control, (25) changes in U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, (26) the results of our efforts to use technology and resilience initiatives to drive efficiencies, better outcomes and an enhanced patient experience, (27) the ability of the Company to realize the assumptions underlying its expectations for growth and (28) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All references to “Company,” “HCA” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

 

3

EX-101.SCH 3 hca-20231109.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 hca-20231109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 hca-20231109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g263099g69j53.jpg GRAPHIC begin 644 g263099g69j53.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 09, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000860730
Document Type 8-K
Document Period End Date Nov. 09, 2023
Entity Registrant Name HCA Healthcare, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-11239
Entity Tax Identification Number 27-3865930
Entity Address, Address Line One One Park Plaza
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code (615)
Local Phone Number 344-9551
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $.01 par value per share
Trading Symbol HCA
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 8 d263099d8k_htm.xml IDEA: XBRL DOCUMENT 0000860730 2023-11-09 2023-11-09 false 0000860730 8-K 2023-11-09 HCA Healthcare, Inc. DE 001-11239 27-3865930 One Park Plaza Nashville TN 37203 (615) 344-9551 false false false false Common Stock, $.01 par value per share HCA NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( 'T]:5<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !]/6E7.Q3K,N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>NFGY(Z(N%Z:=0$)B$HA;E'A;1--&B5&[MR<-6R<$#\ Q]B^? M/TMNM1=Z"/@;JG]C< 79*3M$NJ7$GQY>\;F'[ M2*K7F'Y%*^CH<<7.DU^;A_5VPV1=U4W!>5'=;WDMKAMQ<_<^N_[PNPB[P=B= M_&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !]/6E7Y:1UK$L$ "'$ & 'AL+W=O]-V^D+8 FMB6SY)!M)/ MWY5-;'IGUN1%L(WV\4^KU2.)T5ZJ5QUR;L@ACA(]=D)CTMM62_LACYF^D2E/ MX)N-5#$S<*NV+9TJSH(\*(Y:GNOV6C$3B3,9Y<\6:C*2F8E$PA>*Z"R.F7J[ MXY'MR2AE6[[DYO=TH>"N5:H$(N:)%C(ABF_&SI3>WGD= M&Y"W^$/PO3ZY)K8K:RE?[!CQV<\BJP2<'P]BCKE.VW@ MZ?6[^F/>>>C,FFD^D]$7$9AP[ P<$O -RR+S(O=/_-BAKM7S9:3S_V1?M.VX M#O$S;61\# :"6"3%)SL<$W$2T!Z>"?". 5[.7;PHI[QGADU&2NZ)LJU!S5[D M7$KUWRM3'UR12R%^09?(S8MHX. MC]^P2'.$HU-R=%"=X]C-@$2Q",8PX ?R@;_5$>%*+OP->FZ_[2)8W1*KBXJ5 M];5Z2WD="QX^N/Z 0/1*B-YE$ NNA+1U'A"8+;4\N%)>W7EY-]5WOV3K7S)N M+WPK;(4#Y)S%M62XSM-L2IXXBTSH,\6OH #\&P1O4.(-+L$#-:E2J7)3($L# MR2,SF4&M07,WDE%5G)?ORCA OD9Z= MIPV*[;[G8D9'JZ6 XF:>C^$4]H[G47"!GWNT^PN&4BT(%/?QC]*'K"Q"F6#& MT2#2[G2NA]TNQ8BJ98#B_OU%"6-X JF)XRPYFH:NI<*%FC84M+)^BEOT4D;" M%T8D6_()"EP)%M7RX"J-/)794]RI%XKGZ>$PPXH]!6R]8'/X>;,Y,WZX7A.9 M5[F^AUOT=V3/6F= U@38(-L(6)F^ASOTDON9LM./>FNR$N9;(SSBX"*VA_GJ M+_W7*_+CC4M)RA39L2CC)(5^ZA"V'ACOR:8?]^N58H&MN^5;O):U5=<@ -LA M#*2R>@^WY3)Q#P<_9,F6G]V>-0C-_UQB.QZO+;*6B?'2GM$_\3L&S6)^ :$W)L^N+4J3KW%C9%I?M)<2P/GUOPR MY QF@&T WV^D-.\W]O!:_O8P^0]02P,$% @ ?3UI5Y^@&_"Q @ X@P M T !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%? ME5AV!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK= MT*-SS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G M7$L.IM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y M*GQ#%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W M7AD6#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M, MDP#HG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1! MBEHK'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_ MD/.?K7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[ M:)'-M[#/)73)>UYN1]76^T$D7O!9QP<&%Y M_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J6 M9? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE M 0^L"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ ?3UI M5Y>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5 MN %(MB6/:(7->=I3W; M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II% MR=.B':5_'FR-9V87 MYTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X3[+ MO,&@EXN1:T/9=1,92L88!.R '<(Y_A^[<#K3P&]'@!6^A< MJU3'\TLDO,3 QFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C? MZ/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q; M#X&'' E<)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,, M:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %0 M2P,$% @ ?3UI5R0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688& MO-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S" M:+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X M=/X!4$L#!!0 ( 'T]:5=ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP M97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI* MH!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJU MDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7 MQ<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!Z MVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$ M?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( 'T]:5?E MI'6L2P0 (<0 8 " @0X( !X;"]W;W)K&PO7BKL

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !] M/6E799!YDAD! #/ P $P @ &E$@ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "0 ) #X" #O$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d263099d8k.htm hca-20231109.xsd hca-20231109_lab.xml hca-20231109_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d263099d8k.htm": { "nsprefix": "hca", "nsuri": "http://hcahealthcare.com/20231109", "dts": { "inline": { "local": [ "d263099d8k.htm" ] }, "schema": { "local": [ "hca-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "hca-20231109_lab.xml" ] }, "presentationLink": { "local": [ "hca-20231109_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "report": { "R1": { "role": "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-09_to_2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d263099d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-09_to_2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d263099d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://hcahealthcare.com//20231109/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-23-274071-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-274071-xbrl.zip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end